-+ 0.00%
-+ 0.00%
-+ 0.00%

Aljazira Capital Lifts Rating on Dr. Sulaiman Al Habib Medical Services Group After Q2 Results Beat

MT Newswires·07/27/2026 03:56:57
Listen to the news
03:56 AM EDT, 07/27/2026 (MT Newswires) -- Aljazira Capital upgraded its investment view on Dr. Sulaiman Al Habib Medical Services Group (SASE:4013), taking note of the medical group's second-quarter results. "Dr. Sulaiman Al Habib delivered a strong set of Q2-26 results, with earnings surpassing both our estimates and consensus expectations, supported by robust revenue growth and a stronger-than-anticipated recovery in gross margins," the research firm said in a Sunday research note. "Furthermore, following the recent 19.4% correction in the share price over the past six months, the current valuation offers an attractive entry point. Accordingly, we upgrade our rating on the stock to "Overweight" with a target price SAR 270.7/share." For the second quarter, the company posted a 12.1% annual increase in its net profit to 663 million Saudi riyals, which exceeded Aljazira Capital's estimate of 630 million riyals. The medical group's revenue of 4.01 billion riyals also surpassed the 3.85 billion-riyal estimate of the research firm.